Skip to main
  1. Stocks
  2. MDxHealth SA
  3. Forecast
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is attractive because it has been refocused into a pure-play prostate cancer diagnostics business after discontinuing Resolve, removing the $10.4M Novitas liability, and strengthening financial flexibility with a pro forma cash balance of about $39M. Its growth thesis is supported by Q2'26 revenue of $27.2M, up 16% Y/Y and above estimates, plus reiterated 2026 revenue guidance of $110M-$115M, while the recent $15M Exosome Diagnostics acquisition adds a market-leading EPI test and is expected to contribute $20M+ of revenue in 2026. The company also benefits from secular tailwinds in a urology market expected to grow 5%-10%+, with ProtecT, GPS, and NCCN evidence potentially widening adoption and supporting a move toward positive Adj. EBITDA in Q4'26 and about 20% margin exiting 2028.

Bears say

MDxHealth is facing a deteriorating fundamental profile after pre-announcing Q3 revenue of $22.7M, down 5% year over year and 17% sequentially, while tissue volumes and liquid-based test volumes also missed expectations, signaling weaker commercial execution. The company’s decision to suspend its 2026 revenue guidance, despite less than one quarter remaining in the year, undermines confidence in visibility and suggests the Resolve UTI wind-down and unexpected sales rep turnover materially disrupted growth momentum. Balance sheet concerns further pressure the outlook, with only $31.7M of cash against remaining contingent payments of $18M in 2027 and $21M in 2028, alongside other liabilities and heightened reimbursement, competition, and pricing risks.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

MDxHealth SA (MDXH) Analyst Forecast & Price Prediction

Get the latest MDxHealth SA (MDXH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MDxHealth SA (MDXH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


MDxHealth SA (MDXH) Analyst Forecast & Price Prediction

Get the latest MDxHealth SA (MDXH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MDxHealth SA (MDXH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MDXH stock data and trends